Athena Athena

X
[{"orgOrder":0,"company":"Advent","sponsor":"The Jenner Institute, Oxford University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Advent","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Advent Therapeutics Awarded $3 Million NIH Grant for Novel Neonatal Lung Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Advent

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The grant will allow the Company to position its novel aerosolized retinol palmitate (vitamin A) formulation for commercialization in 2025 to prevent Bronchopulmonary Dysplasia (BPD).

            Lead Product(s): Vitamin A Palmitate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $3.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Jenner Institute at the University of Oxford has agreed a contract with Advent Srl, to produce the first batch of the novel coronavirus vaccine ChAdOx1 nCoV-19 for clinical testing.

            Lead Product(s): ChAdOx1

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: The Jenner Institute, Oxford University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY